Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
medical food with AN777, nutritional formula · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| medical food with AN777 | EXPERIMENTAL | - |
| oral nutritional formula | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| medical food with AN777 | OTHER | Two(220 mL)servings every day for six months |
| oral nutritional formula | OTHER | Two (220 mL) servings daily for six months |
Inclusion Criteria: Subject (male or female) is \> or equal to 65 and \< or equal to 90 years of age Subject is ambulatory Subject has a Subjective Global Assessment of B or C Subject has gait speed \<0.8 m/s AND/OR low hand-grip strength Subject has Class 1 or Class 2 sarcopenia Subject agree...
AN777 is a medical food, a nutritional formula being studied for use in malnutrition. It is being evaluated in older adults, specifically for conditions including malnutrition and sarcopenia. The product is under development by Abbott Laboratories.
Abbott Laboratories (NYSE: ABT) is the developer of AN777, a medical food nutritional formula. The company is conducting clinical research on this product for malnutrition and sarcopenia in older adults.
AN777 is in Phase 3 clinical development. A Phase 3 trial has been completed, evaluating the oral nutritional supplement containing AN777 in 331 participants with malnutrition and sarcopenia.
AN777 has one completed Phase 3 clinical trial, NCT01191125, titled 'Evaluation of an Oral Nutritional Supplement Containing AN777'. The study enrolled 331 participants aged 65 years and older across multiple countries, including the United States, Belgium, Italy, Mexico, Poland, Spain, Switzerland, and the United Kingdom.
AN777 is an investigational medical food and is still in clinical development. It is not approved by the FDA. A Phase 3 trial has been completed, but the product remains under investigation for malnutrition and sarcopenia.